ABSTRACT
Background Anal squamous cell carcinoma is a rare tumor. Chemo-radiotherapy yields a 50% 3-year relapse-free survival rate in advanced anal cancer, so improved predictive markers and therapeutic options are needed.
Methods High-throughput proteomics and whole-exome sequencing were performed in 46 paraffin samples from anal squamous cell carcinoma patients. Hierarchical clustering was used to establish groups de novo. Then, probabilistic graphical models were used to study the differences between groups of patients at the biological process level.
Results A molecular classification into two groups of patients was established, one group with increased expression of proteins related to adhesion, T lymphocytes and glycolysis; and the other group with increased expression of proteins related to translation and ribosomes. The probabilistic graphical model showed that these two groups presented differences in metabolism, mitochondria, translation, splicing and adhesion processes. Additionally, these groups showed different frequencies of genetic variants in some genes, such as ATM, SLFN11 and DST. Finally, genetic and proteomic characteristics of these groups suggested the use of some possible targeted therapies, such as PARP inhibitors or immunotherapy.
Conclusions In this study, a molecular classification of anal squamous cell carcinoma using high-throughput proteomics and whole-exome sequencing data was proposed. Moreover, differences between the two established groups suggested some possible therapies.
Competing Interest Statement
JAFV and AG-P are shareholders in Biomedica Molecular Medicine SL. LT-F and GP-V are employees of Biomedica Molecular Medicine SL. JC has received honoraria for scientific consulting (as speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi and Merck Serono and research support from Eisai, Novartis, Ipsen, Astrazeneca, Pfizer and Advanced Accelerator Applications. IG has received honoraria and/or travel expenses from Roche, Sanofi, Merck, Servier, Amgen and Sirtflex, and for advisory role from Merck and Sanofi. JF has received consulting and advisory honoraria from Amgen, Ipsen, Eissai, Merck, Roche and Novartis; research funding from Merck, and travel and accommodation expenses from Amgen and Servier. The other authors declare no conflicts of interest.
Funding Statement
This study was supported by the Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry, Spain and co-sponsored by the FEDER program, “Una forma de hacer Europa” (PI15/01310), a Roche Farma grant, Cátedra UAM-Amgen and a grant of Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD1403). LT-F is supported by the Spanish Economy and Competitiveness Ministry (DI-15-07614). GP-V is supported by the Consejería de Educación, Juventud y Deporte of Comunidad de Madrid (IND2017/BMD7783); AZ-M is supported by Jesús Antolín Garciarena fellowship from IdiPAZ. The sponsors were not involved in the study design, in data collection and analysis, in the decision to publish or in the preparation of this manuscript.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The proteomics data generated during the current study are available in Chorus repository (https://chorusproject.org/pages/index.html). The exome sequencing data are available in SRA https://www.ncbi.nlm.nih.gov/sra) under the name PRJNA573670.
List of abbreviations
- ASCC
- Anal squamous cell carcinoma
- 5FU
- 5-fluorouracil
- DFS
- disease-free survival
- WES
- whole-exome sequencing
- MS
- mass-spectrometry
- PGM
- probabilistic graphical model
- FFPE
- formalin-fixed paraffin-embedded
- ECOG-PS
- Eastern Cooperative Oncology Group performance status
- HPV
- Human papilloma virus
- VEP
- Variant Effect Predictor
- DDA
- Data-dependent acquisition
- FDR
- False Discovery Rate
- FBA
- Flux Balance Analysis
- BIC
- Bayesian Information Criterion
- GPR
- Gene-Protein-Reaction rules
- SAM
- Significance Analysis of Microarrays
- PARPi
- PARP inhibitors
